Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease.
Olga O VlashynAshley M LorenzMohammad Mahdee E SobhanieJessica M SmithMegan BondLynn C WardlowPublished in: Journal of clinical pharmacy and therapeutics (2020)
In a cohort of patients with severe renal dysfunction treated with daptomycin 7.5 mg/kg or greater, significant CK elevation on daptomycin therapy was infrequently observed. Future research should confirm these findings, with special consideration for higher mg/kg dosages and/or obese populations.
Keyphrases
- end stage renal disease
- methicillin resistant staphylococcus aureus
- chronic kidney disease
- high dose
- peritoneal dialysis
- acute kidney injury
- cardiac surgery
- adipose tissue
- low dose
- metabolic syndrome
- oxidative stress
- weight loss
- type diabetes
- current status
- early onset
- stem cells
- mesenchymal stem cells
- drug induced
- newly diagnosed
- cell therapy
- bone marrow